Latest Top Picks

Stock Opinions by Neil Murdock

BUY
Well below its intrinsic value.
DON'T BUY
Not happy with their acquisition.
BUY
Fantastic business. Well run.
TOP PICK
A good market that has grown steadily. Earnings per share are up 120%. 8 X earnings.
HOLD
Well run and strong management. Has grown so big that future growth is difficult.
BUY ON WEAKNESS
Very successful biotech. Big growth. May be a little high.
DON'T BUY
Still needs capital expenditure to grow.
DON'T BUY
Still needs capital expenditure to grow.
HOLD
Has had management problems.
DON'T BUY
Has had a lot of free cash flow. Cost cutting. Hard to get more revenue growth.
DON'T BUY
Reasonable good value, but thinks they will have trouble expanding globally.
BUY
Strong brand name. Good management. Strong yield.
DON'T BUY
Would prefer others.
DON'T BUY
Prefers Pfizer.
STRONG BUY
Great product line/sales force. Good price.
Showing 1 to 15 of 125 entries